Publisher Correction: CD3ζ ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides

Affiliations

• ¹ Hematopoiesis and Lymphocyte Biology Section, Eunice Kennedy Shriver, National Institute of Child Health and Human Development, Bethesda, MD, USA.
• ² Immunodynamics Section, Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
• ³ Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
• ⁴ Département de Biochimie et Médecine Moléculaire, Université de Montréal, Montréal, Quebec, Canada.
• ⁵ Department of Physics, McGill University, Montréal QC, Canada.
• ⁶ Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
• ⁷ Department of Safety Assessment, Genentech, Inc., San Francisco, CA, USA.
• ⁸ Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
• ⁹ Viral Immunology & Intravital Imaging Section, National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA.
• ¹⁰ National Institutes of Health Library, Office of Research Services, National Institutes of Health, Bethesda, MD, USA.
• ¹¹ Duncan and Nancy MacMillan Cancer Immunology and Metabolism Center of Excellence, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
• ¹² Mila Québec, Montréal, Quebec, Canada.
• ¹³ Hematopoiesis and Lymphocyte Biology Section, Eunice Kennedy Shriver, National Institute of Child Health and Human Development, Bethesda, MD, USA. [email protected].